Ligand Pharmaceuticals
LGND
271 hedge funds and large institutions have $2.18B invested in Ligand Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 111 increasing their positions, 87 reducing their positions, and 23 closing their positions.
10,027% more call options, than puts
Call options by funds: $1.11M | Put options by funds: $11K
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
43% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 23
28% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 87
11% more capital invested
Capital invested by funds: $1.97B → $2.18B (+$211M)
3% more funds holding
Funds holding: 262 → 271 (+9)
2.28% more ownership
Funds ownership: 97.22% → 99.5% (+2.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$36M |
| 2 |
RIM
Ranger Investment Management
Dallas,
Texas
|
+$11.8M |
| 3 |
PCMF
Private Capital Management (Florida)
Naples,
Florida
|
+$8.67M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$6.62M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$4.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Castleark Management
Chicago,
Illinois
|
-$6.99M |
| 2 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
-$5.86M |
| 3 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$4.74M |
| 4 |
LCG
Lisanti Capital Growth
New York
|
-$4.48M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$4.32M |
LGND Hedge Fund Activity: Q2 2025 in Review
271 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2025, worth a combined $2.18B — up 11% from $1.97B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new LGND positions and 23 closed out — a net gain of 10 holders — while 111 added to existing stakes and 87 trimmed.
The largest buyer was UBS AM, adding an estimated $36M. The largest seller was Castleark Management, exiting entirely with an estimated $6.99M sold.
- 271 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2025, up from 262 in Q1 2025.
- Funds reported $2.18B of Ligand Pharmaceuticals stock for Q2 2025, up 11% quarter-over-quarter.
- 33 funds opened new Ligand Pharmaceuticals positions in Q2 2025 and 23 closed out, a net change of +10 holders.
- The largest Ligand Pharmaceuticals buyer in Q2 2025 was UBS AM, an estimated $36M added.
- The largest Ligand Pharmaceuticals seller in Q2 2025 was Castleark Management, an estimated $6.99M sold.
Based on aggregated 13F filings for Q2 2025.